KT

Kalaris Therapeutics Inc

KLRS·NASDAQ

$4.70

-0.42%
HealthcareBiotechnology

Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.

At a Glance

Live Snapshot
Market Cap$87.90M
EPS-2.8500
P/E Ratio-1.65
Earnings Date08/12/2026

klrs

Other Current Liabilities

Last Annual Value

6.52M

3-Year CAGR

180%

5-Year CAGR

6%

10-Year CAGR

3%

KT

Kalaris Therapeutics Inc Competitors Analysis of Other Current Liabilities

KLRS · NASDAQ
CompanyOther Current Liabilities
CAGR 3Y
CAGR 5Y
CAGR 10Y
6.52M
129.4%-15.4%N/A 
0.00
N/AN/AN/A
10.03M
N/AN/AN/A
4.95M
0.8%-15.1%N/A
5.38M
101.1%128.9%N/A
6.72M
16.9%3.0%N/A
5.96M
-12.1%-4.6%4.1%
14.42M
29.1%32.5%N/A
6.00M
10.8%3.2%N/A
8.83M
-7.8%N/AN/A
0.00
N/AN/AN/A
KT

Kalaris Therapeutics Inc Fair Value Envelope

KLRS · NASDAQ

Our analysis suggests that KLRS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.7, this represents a potential HIDDEN relative to our calculated worth for Kalaris Therapeutics Inc.

Intrinsic Value
Current Price: $4.7